Reports of Biochemistry
and Molecular Biology
Thu, Nov 21, 2024
[Archive]
Volume 11, Issue 4 (Vol.11 No.4 Jan 2023)
rbmb.net 2023, 11(4): 710-719 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rasti A, Khalili M, Fakhr Yasseri A M, Nasirian N, Shirkoohi R, Nowroozi M R et al . Evaluation of IGF2, KRT14, and KRT20 as Urinary Biomarkers in Patients with Bladder Cancer. rbmb.net 2023; 11 (4) :710-719
URL: http://rbmb.net/article-1-1066-en.html
URL: http://rbmb.net/article-1-1066-en.html
Azam Rasti 
, Masoud Khalili , Ali Mohammad Fakhr Yasseri , Neda Nasirian , Reza Shirkoohi , Mohammad Reza Nowroozi , Mohammad Hossein Modarressi *
, Masoud Khalili , Ali Mohammad Fakhr Yasseri , Neda Nasirian , Reza Shirkoohi , Mohammad Reza Nowroozi , Mohammad Hossein Modarressi *
Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Abstract: (1748 Views)
Background: Many researchers have tried to identify bladder cancer biomarkers to reduce the need for cystoscopy. The aim of this study was to identify and measure appropriate transcripts in patient urine to develop a non-invasive screening test.
Methods: From February 2020 to May 2022, 49 samples were obtained from Velayat Hospital, Qazvin University of Medical Sciences, Qazvin, Iran. Twenty-two samples were obtained from bladder cancer patients and 27 from bladder cancer-free subjects. RNA was extracted from participant samples, quantitative RT-PCR was performed, and TNP plots were used to assess IGF2 (NCBI Gene ID: 3481), KRT14 (NCBI Gene ID: 3861) and KRT20 (NCBI Gene ID: 54474) expression. For UCSC Xena analysis, Dataset ID: TCGA-BLCA was used to compare transitional cell carcinoma (TCC) and normal samples for survival rates.
Results: IGF and KRT14 were more greatly expressed in patient urine samples than in those of the normal group. However, KRT20 expression did not significantly differ between the two groups. IGF2 had 45.45 and 88.89% sensitivity and specificity, respectively, for detecting TCC in urine samples while KRT14 had 59 and 88.89% sensitivity and specificity, respectively. Also, these results infer that overexpression of IGF would be prognosticators of poor TCC outcomes.
Conclusions: Our study showed that IGF2 and KRT14 are overexpressed in bladder cancer patient urine, and IGF2 could be a potential biomarker for poor prognoses in TCC.
Methods: From February 2020 to May 2022, 49 samples were obtained from Velayat Hospital, Qazvin University of Medical Sciences, Qazvin, Iran. Twenty-two samples were obtained from bladder cancer patients and 27 from bladder cancer-free subjects. RNA was extracted from participant samples, quantitative RT-PCR was performed, and TNP plots were used to assess IGF2 (NCBI Gene ID: 3481), KRT14 (NCBI Gene ID: 3861) and KRT20 (NCBI Gene ID: 54474) expression. For UCSC Xena analysis, Dataset ID: TCGA-BLCA was used to compare transitional cell carcinoma (TCC) and normal samples for survival rates.
Results: IGF and KRT14 were more greatly expressed in patient urine samples than in those of the normal group. However, KRT20 expression did not significantly differ between the two groups. IGF2 had 45.45 and 88.89% sensitivity and specificity, respectively, for detecting TCC in urine samples while KRT14 had 59 and 88.89% sensitivity and specificity, respectively. Also, these results infer that overexpression of IGF would be prognosticators of poor TCC outcomes.
Conclusions: Our study showed that IGF2 and KRT14 are overexpressed in bladder cancer patient urine, and IGF2 could be a potential biomarker for poor prognoses in TCC.
Type of Article: Original Article |
Subject:
Molecular Biology
Received: 2022/10/17 | Accepted: 2022/12/24 | Published: 2023/04/3
Received: 2022/10/17 | Accepted: 2022/12/24 | Published: 2023/04/3
References
1. Schmitz-Dräger BJ, Droller M, Lokeshwar VB, Lotan Y, Hudson MA, van Rhijn BW, et al. Molecular markers for bladder cancer screening, early diagnosis, and surveillance: the WHO/ICUD consensus. Urol Int. 2015;94(1):1-24.
https://doi.org/10.1159/000050935 [DOI:10.1159/000369357]
2. Montalbo R, Lozano JJ, Izquierdo L, Ingelmo-Torres M, BaÑos C, Palou J, et al. Ability of a urine gene expression classifier to reduce the number of follow-up cystoscopies in bladder cancer patients. Transl Res. 2019;208:73-84. [DOI:10.1016/j.trsl.2019.02.003] [PMID]
3. Guitynavard F, Azadvari M, Reis LO, Sheikh M. Chapter 4 - Liquid biopsy in bladder tumors. In: Liquid Biopsy in Urogenital Cancers and its Clinical Utility: Academic Press; 2022;45-65. [DOI:10.1016/B978-0-323-99884-0.00008-2]
4. Crocetto F, Barone B, Ferro M, Busetto GM, La Civita E, Buonerba C, et al. Liquid biopsy in bladder cancer: State of the art and future perspectives. Crit Rev Oncol Hematol. 2022;170:103577. [DOI:10.1016/j.critrevonc.2022.103577] [PMID]
5. Lodewijk I, Dueñas M, Rubio C, Munera-Maravilla E, Segovia C, Bernardini A, et al. Liquid Biopsy Biomarkers in Bladder Cancer: A Current Need for Patient Diagnosis and Monitoring. Int J Mol Sci. 2018;19(9):2514. [DOI:10.3390/ijms19092514] [PMID] [PMCID]
6. Shafieian Z, Bahari G, Hashemi M, Nakhaee A. SIRT1 Gene Polymorphisms Are Associated with Urinary Bladder Cancer in an Iranian Population. Rep Biochem Mol Biol. 2019;8(2):194-199.
7. Zhao SG, Chen WS, Das R, Chang SL, Tomlins SA, Chou J, et al. Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas. Clin Cancer Res. 2019;25(8):2450-2457. [DOI:10.1158/1078-0432.CCR-18-3121] [PMID]
8. Bartha Á, Győrffy B. TNMplot.com: A Web Tool for the Comparison of Gene Expression in Normal, Tumor and Metastatic Tissues. Int J Mol Sci. 2021;22(5):2622. [DOI:10.3390/ijms22052622] [PMID] [PMCID]
9. Goldman MJ, Craft B, Hastie M, Repečka K, McDade F, Kamath A, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38(6):675-678. [DOI:10.1038/s41587-020-0546-8] [PMID] [PMCID]
10. Habibi S, Jamshidian H, Kadivar M, Eshraghian MR, Javanbakht MH, Derakhshanian H, Djalali M. A study of lipid- and protein- bound sialic acids for the diagnosis of bladder cancer and their relationships with the severity of malignancy. Rep Biochem Mol Biol. 2014;2(2):70-5.
11. Partin AW, Wein AJ, Kavoussi LR, Peters CA, Dmochowski RR. Campbell Walsh Wein Urology, y, 12th Edition; E-Book: Elsevier Health Sciences; 2020.
12. Oge O, Kozaci D, Gemalmaz H. The BTA stat test is nonspecific for hematuria: an experimental hematuria model. J Urol. 2002;167(3):1318-20. [DOI:10.1016/S0022-5347(05)65290-1] [PMID]
13. Malinaric R, Mantica G, Lo Monaco L, Mariano F, Leonardi R, Simonato A, et al. The Role of Novel Bladder Cancer Diagnostic and Surveillance Biomarkers-What Should a Urologist Really Know? Int J Environ Res Public Health. 2022;19(15):9648. [DOI:10.3390/ijerph19159648] [PMID] [PMCID]
14. Hedegaard J, Lamy P, Nordentoft I, Algaba F, Høyer S, Ulhøi BP, et al. Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma. Cancer Cell. 2016;30(1):27-42. [DOI:10.1016/j.ccell.2016.05.004] [PMID]
15. Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, et al. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. 2017;171(3):540-556.e25.
16. Salomo K, Huebner D, Boehme MU, Herr A, Brabetz W, Heberling U, et al. Urinary transcript quantitation of CK20 and IGF2 for the non-invasive bladder cancer detection. J Cancer Res Clin Oncol. 2017;143(9):1757-1769. [DOI:10.1007/s00432-017-2433-3] [PMID]
17. El-Abd A, Sherif H, Abdallah O, M Abdel-Hamied O, AbdElkareem H, Habashy O. Evaluation of IGF-2 Gene Expression in Urine and its Potential Use as Biomarker for Bladder Cancer Benha Journal of Applied Sciences. 2021;6(2):255-7. [DOI:10.21608/bjas.2021.169460]
18. Chiu YF, Wu CC, Kuo MH, Miao CC, Zheng MY, Chen PY, et al. Critical role of SOX2-IGF2 signaling in aggressiveness of bladder cancer. Sci Rep. 2020;10(1):8261. [DOI:10.1038/s41598-020-65006-z] [PMID] [PMCID]
19. Wu H, Li Y, Cui H, Wu W, Yang H, Yang X, et al. IGF2/IGF2R expression in urothelial bladder cancer and its implications for tumor recurrence and prognosis. Int J Clin Exp Med 2017;10(1):881-888.
20. de Jong JJ, Boormans JL, van Rhijn BWG, Seiler R, Boorjian SA, Konety B, et al. Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences. Eur Urol Oncol. 2020;3(4):420-423. [DOI:10.1016/j.euo.2020.02.010] [PMID]
21. Dobruch J, Daneshmand S, Fisch M, Lotan Y, Noon AP, Resnick MJ, et al. Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes. Eur Urol. 2016;69(2):300-10. [DOI:10.1016/j.eururo.2015.08.037] [PMID]
22. Ingenwerth M, Nyirády P, Hadaschik B, Szarvas T, Reis H. The Prognostic Value of Cytokeratin and Extracellular Collagen Expression in Urinary Bladder Cancer. Curr Mol Med. 2022;22(10):941-949. [DOI:10.2174/1566524021666210225100041] [PMID]
23. Ramírez-Backhaus M, Fernández-Serra A, Rubio- Briones J, Cruz Garcia P, Calatrava A, Garcia Casado Z, et al. External validation of FXYD3 and KRT20 as predictive biomarkers for the presence of micrometastasis in muscle invasive bladder cancer lymph nodes. Actas Urol Esp. 2015;39(8):473-81. [DOI:10.1016/j.acuro.2015.02.002] [PMID]
24. Schulz A, Loloi J, Pina Martina L, Sankin A. The Development of Non-Invasive Diagnostic Tools in Bladder Cancer. Onco Targets Ther. 2022;15:497-507. [DOI:10.2147/OTT.S283891] [PMID] [PMCID]
25. Soputro NA, Gracias DN, Dias BH, Nzenza T, O'Connell H, Sethi K. Utility of urinary biomarkers in primary haematuria: Systematic review and meta-analysis. BJUI Compass. 2022;3(5):334-343. [DOI:10.1002/bco2.147] [PMID] [PMCID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
